You are here: Industry Insights > Monoclonal Antibodies

News List

Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(2) Siyi
June 06, 2018
Enbrel and Remicade have begun to suffer impacts of generic drugs, with market shares largely reducing.
Anti-PD-1/PD-L1 Monoclonal Antibodies: Not Easy to Let Go (2) Mr. Nanguo
May 02, 2018
Whether products have unique advantages is a criterion for considering whether they can be further advanced.
Anti-PD-1/PD-L1 Monoclonal Antibodies: Not Easy to Let Go (1) Mr. Nanguo
May 02, 2018
Anti-PD-1/PD-L1 monoclonal antibodies, the trailbreaker of tumor immunotherapies, have been chased after by the market since marketing, and become the battleground of international pharmaceutical giants.
Current Situation of Biosimilars in China III: Analysis of Biosimilars of Five Blockbusts Tang
January 16, 2018
The biosimilars in China just started, and the biosimilar review and approval policies continue to be improved.
Current Situation of Biosimilars in China III: Analysis of Biosimilars of Five Blockbust Tang
December 27, 2017
The biosimilars in China just started, and the biosimilar review and approval policies continue to be improved.
New Shigella Monoclonal Antibodies pharmaasia
April 05, 2017
Shigella sonnei is the leading cause of disease in industrialized countries and Shigella flexneri is the most common species seen in developing countries.
Cancer immunotherapy market to hit 14 percent CAGR to 2021 pharmaasia
March 08, 2017
The global cancer immunotherapy market is set to reach US$19.39 billion by 2021 from US$61.97 billion in 2016 growing at a CAGR of 14 percent
New Zika virus monoclonal antibodies pharmaasia
January 16, 2017
Maine’s biotech company, ViroStat Inc, has come up with a new set of monoclonal antibodies to the NS1 protein of the Zika virus.

Previous page 1 2 Next page